Evidence map›Paper›PMID 27063030›Full record

ReviewExpert review of vaccines2016

Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies.

P Vici, L Pizzuti, L Mariani, G Zampa, D Santini, L Di Lauro, T Gamucci, C Natoli, P Marchetti, M Barba and 13 more

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert review of vaccines, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 3 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 3 syntheses or guidelines pooled it, 96 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Current and future direction in treatment of HPV-related cervical disease.Journal of molecular medicine (Berlin, Germany) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 9 institutions in 3 countries.

P Vicia Division of Medical Oncology 2 , 'Regina Elena' National Cancer Institute , Rome , Italy.
L Pizzutia Division of Medical Oncology 2 , 'Regina Elena' National Cancer Institute , Rome , Italy.
L Marianib HPV-UNIT Laboratory of Virology , 'Regina Elena' National Cancer Institute , Rome , Italy.
G Zampad Oncology Unit , Nuovo Regina Margherita Hospital , Rome , Italy.
D Santinie Department of Medical Oncology , University Campus Bio-Medico , Rome , Italy.
L Di Lauroa Division of Medical Oncology 2 , 'Regina Elena' National Cancer Institute , Rome , Italy.
T Gamuccif Medical Oncology Unit, ASL Frosinone , Frosinone , Italy.
C Natolig Department of Medical, Oral and Biotechnological Sciences, Experimental and Clinical Sciences , University 'G. d'Annunzio' , Chieti , Italy.
P Marchettih Oncology Unit, Sant'Andrea Hospital , 'Sapienza' University of Rome , Rome , Italy.
M Barbaa Division of Medical Oncology 2 , 'Regina Elena' National Cancer Institute , Rome , Italy.
M Maugeri-Saccàa Division of Medical Oncology 2 , 'Regina Elena' National Cancer Institute , Rome , Italy.
D Sergia Division of Medical Oncology 2 , 'Regina Elena' National Cancer Institute , Rome , Italy.
F Tomaoj Department of Gynecologic and Obstetric Sciences , La Sapienza University of Rome , Rome , Italy.
E Vizzab HPV-UNIT Laboratory of Virology , 'Regina Elena' National Cancer Institute , Rome , Italy.
S Di Filippok Emergency Department , Santa Maria Goretti Hospital , Latina , Italy.
F Paolinib HPV-UNIT Laboratory of Virology , 'Regina Elena' National Cancer Institute , Rome , Italy.
G Curziob HPV-UNIT Laboratory of Virology , 'Regina Elena' National Cancer Institute , Rome , Italy.
G Corradoc Department of Gynecologic Oncology , 'Regina Elena' National Cancer Institute , Rome , Italy.
A Michelottil Oncology Unit I , Azienda Ospedaliera Universitaria Pisana , Pisa , Italy.
G Sanguinetim Radiotherapy , 'Regina Elena' National Cancer Institute , Rome , Italy.
A Giordanon Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology , Temple University , Philadelphia , PA , USA.
R De Mariai Scientific Direction , 'Regina Elena' National Cancer Institute , Rome , Italy.
A Venutib HPV-UNIT Laboratory of Virology , 'Regina Elena' National Cancer Institute , Rome , Italy.
National Cancer Institute · MYSapienza University of Rome · ITAccademia di Belle Arti di Frosinone · ITAzienda Ospedaliera Universitaria Pisana · ITOspedale Regina Margherita · ITOspedale Santa Maria Goretti · ITTemple University · USUniversità Campus Bio-Medico · ITUniversity of Chieti-Pescara · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human papillomavirus (HPV) is widely known as a cause of cervical cancer (CC) and cervical intraepithelial neoplasia (CIN). HPVs related to cancer express two main oncogenes, i.e. E6 and E7, considered as tumorigenic genes; their integration into the host genome results in the abnormal regulation of cell cycle control. Due to their peculiarities, these oncogenes represent an excellent target for cancer immunotherapy. In this work the authors highlight the potential use of therapeutic vaccines as safe and effective pharmacological tools in cervical disease, focusing on vaccines that have reached the clinical trial phase. Many therapeutic HPV vaccines have been tested in clinical trials with promising results. Adoptive T-cell therapy showed clinical activity in a phase II trial involving advanced CC patients. A phase II randomized trial showed clinical activity of a nucleic acid-based vaccine in HPV16 or HPV18 positive CIN. Several trials involving peptide-protein-based vaccines and live-vector based vaccines demonstrated that these approaches are effective in CIN as well as in advanced CC patients. HPV therapeutic vaccines must be regarded as a therapeutic option in cervical disease. The synergic combination of HPV therapeutic vaccines with radiotherapy, chemotherapy, immunomodulators or immune checkpoint inhibitors opens a new and interesting scenario in this disease.

Indexed as

Cancer VaccinesClinical Trials as TopicDrug DiscoveryFemaleHumansPapillomavirus InfectionsUterine Cervical NeoplasmsCancer Vaccinescervical cancercervical intraepithelial neoplasiaHuman papillomavirusimmunotherapytherapeutic vaccines

Identifiers

PMID27063030
PMCPMC5152541
OpenAlexW2330158443

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.